Scienture Holdings ((SCNX)) just revealed the announcement.
On March 4, 2025, Scienture Holdings, Inc., signed an exclusive commercial and supply contract with Summit Biosciences Inc., a subsidiary of Kindeva Drug Delivery LP, to rezenopy® (Naloxone HCL Spray 10mg) in the United States. We have given you a monopoly right to commercialize. This agreement allows you to priced, launch and market products for overdose of opioid overdose and to fight. Cooperation with Kindeva, which will handle manufacturing, coincides with the mission of Scienture to provide innovative treatment solutions, and indicates a strategic step in developing public health initiatives. This contract includes a joint steering committee to supervise the activities, and Scienture requires KINDEVA to pay milestones and profits.
For more information about Sai Under Holding
Scienture Holdings, Inc., is a subsidiary, developing and distributing new special pharmaceutical products to meet the unprecedented market demands, and focuses on providing improved value to patients, doctors and caregivers. The company operates in the pharmaceutical industry and provides both brands and general products in various treatment areas.
YTD price performance: -73.68%
Average trading volume: 901,090
Technical sentiment consensus rating: Strong purchase
Current market capitalization: $ 14.21m
To see more information about SCNX stocks Tipranks’ stock analysis page.
